Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/151378
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, Wei Qien_US
dc.contributor.authorYang, Guangbaoen_US
dc.contributor.authorPhua, Fiona Soo Zengen_US
dc.contributor.authorChen, Hongzhongen_US
dc.contributor.authorZhao, Yanlien_US
dc.date.accessioned2021-06-15T00:55:31Z-
dc.date.available2021-06-15T00:55:31Z-
dc.date.issued2019-
dc.identifier.citationLim, W. Q., Yang, G., Phua, F. S. Z., Chen, H. & Zhao, Y. (2019). Self-assembled oxaliplatin(IV) prodrug-porphyrin conjugate for combinational photodynamic therapy and chemotherapy. ACS Applied Materials and Interfaces, 11(18), 16391-16401. https://dx.doi.org/10.1021/acsami.9b04557en_US
dc.identifier.issn1944-8244en_US
dc.identifier.other0000-0002-9506-4079-
dc.identifier.other0000-0002-9231-8360-
dc.identifier.urihttps://hdl.handle.net/10356/151378-
dc.description.abstractNanomedicine has emerged as a promising strategy for effective cancer treatment. A useful approach is to develop carrier-free nanodrugs via a facile supramolecular self-assembly process. To achieve high therapeutic effect, integrating photodynamic therapy with chemotherapy has been sought after. In this work, we designed a nanocarrier (PEG-Por-CD: oxliPt(IV)-ada) assembled with oxaliplatin prodrug (oxliPt(IV)-ada) and porphyrin photosensitizer (PEG-Por-CD) through host-guest interaction to achieve stimulus-responsive combination therapy. Contributed by excellent spatial control of the binding ratio between host and guest molecules, porphyrin and oxaliplatin were separately modified with β-cyclodextrin and adamantane to prepare the amphiphilic host-guest complex for subsequent self-assembly into therapeutic nanoparticles. The obtained PEG-Por-CD: oxliPt(IV)-ada nanoparticles exhibited good colloidal stability with an average hydrodynamic size of 164 nm while undergoing the disassembly under reductive environment to release active therapeutic species. Confocal imaging demonstrated the ability of PEG-Por-CD: oxliPt(IV)-ada to effectively accumulate in the cells and produce reactive oxygen species in vitro upon 630 nm light irradiation. As compared with the monotherapy, the PEG-Por-CD: oxliPt(IV)-ada nanoparticles exhibited 3-fold enhanced cytotoxicity and 2-fold increase in the apoptosis. In vivo experiments using 4T1 tumor-bearing mice confirmed that the nanoparticles were efficient in suppressing the tumor growth without eliciting systemic toxicity. The present self-delivery nanosystem constructed from the self-assembly approach not only allows precise control over the drug and photosensitizer loading ratio but also eliminates systemic toxicity concern of the drug carriers, providing a solution for further development of combinational cancer treatment.en_US
dc.description.sponsorshipAgency for Science, Technology and Research (A*STAR)en_US
dc.description.sponsorshipMinistry of Education (MOE)en_US
dc.description.sponsorshipNational Research Foundation (NRF)en_US
dc.language.isoenen_US
dc.relationRG5/16en_US
dc.relationRG11/17en_US
dc.relationRG114/17en_US
dc.relationA1883c0005en_US
dc.relationNRF-NRFI2018-03en_US
dc.relation.ispartofACS Applied Materials and Interfacesen_US
dc.rights© 2019 American Chemical Society. All rights reserved.en_US
dc.subjectScience::Chemistryen_US
dc.titleSelf-assembled oxaliplatin(IV) prodrug-porphyrin conjugate for combinational photodynamic therapy and chemotherapyen_US
dc.typeJournal Articleen
dc.contributor.schoolSchool of Physical and Mathematical Sciencesen_US
dc.contributor.schoolInterdisciplinary Graduate School (IGS)en_US
dc.contributor.researchNTU-Northwestern Institute for Nanomedicineen_US
dc.identifier.doi10.1021/acsami.9b04557-
dc.identifier.pmid31002492-
dc.identifier.scopus2-s2.0-85065497872-
dc.identifier.issue18en_US
dc.identifier.volume11en_US
dc.identifier.spage16391en_US
dc.identifier.epage16401en_US
dc.subject.keywordsChemotherapyen_US
dc.subject.keywordsCombinational Therapyen_US
dc.description.acknowledgementThis research was supported by the Singapore Academic Research Fund (Nos. RG5/16, RG11/17, and RG114/17), the Singapore Agency for Science, Technology and Research (A*STAR) AME IRG grant (No. A1883c0005), and the Singapore National Research Foundation Investigatorship (No. NRF-NRFI2018-03).en_US
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Collections:IGS Journal Articles
SPMS Journal Articles

SCOPUSTM   
Citations 10

21
Updated on Jun 29, 2021

PublonsTM
Citations 10

20
Updated on Jun 22, 2021

Page view(s)

64
Updated on Oct 18, 2021

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.